the avoca quality consortium welcomes takeda pharmaceuticals
TRANSCRIPT
FOR IMMEDIATE RELEASE Contact Brittany Hutt – 610-‐212-‐1230 [email protected]
Avoca Quality Initiative Gains Pace with New Membership – Welcomes Takeda Pharmaceuticals
Princeton, NJ (August 20, 2014) -‐ Takeda Pharmaceuticals has joined The Avoca Quality Consortium and aligned with the collaborative industry effort to improve efficiency and quality and reduce risk through the acceleration of best practice and the adoption of improved standards. The Avoca Quality Consortium, with 36 members, now represents over half of the top Pharma companies and CROs. The collaborative is a catalyst for industry progress through the delivery of industry wide quality solutions. Patty Leuchten, CEO of The Avoca Group commented, “The Consortium was pioneered by Avoca and has been embraced by the key stakeholders in the clinical development enterprise. The Avoca Quality Consortium continues on a journey to transform the trial process and get new medicines to patients faster and we are delighted that Takeda Pharmaceuticals has joined the effort.” Member companies are already able to access best practice guidelines and tools for governance, process oversight, communication, oversight leadership requirements, roles and responsibilities, and metrics/analytics/technology. Guidelines and tools for proactive risk and opportunity management and technology oversight will be delivered by end of year. In 2014, The Avoca Quality Consortium also initiated a new program focused on prequalification of technical service providers, including the selecting of five initial service areas – Core Labs, Imaging, IRT, ECG, and Biomarkers – and the development of industry standards. Steve Whittaker, Executive Director of The Avoca Quality Consortium added, “Members are embracing initiatives that promote a sea change in the pharma industry and advance progress through collaboration. Via the Avoca Quality Consortium's initiatives for the development of best practice guidelines, tools, templates, and metric designs,
we are advancing the use of technology, the engagement of patients, and the sharing of methodologies that collectively will add greater capability and efficiency across the industry for the conduct of clinical programs." About Takeda Pharmaceuticals International, Inc. Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-‐owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the largest pharmaceutical company in Japan. Takeda Pharmaceuticals International, Inc. is the hub for R&D excellence and the commercial activities in Americas and Europe as well as other strategic functions of Takeda group. It is committed to maximize the global market potential of new products and the company’s international presence to realize Takeda’s Mission to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com. About The Avoca Quality Consortium The Avoca Quality Consortium was founded in 2012 to bring Sponsors and CROs together to accelerate the development of best practices and industry standards for proactive quality management in clinical trials. The Avoca Group Inc, leads the Avoca Quality Consortium and offers research, consulting and training solutions with a team of pharmaceutical industry veterans and subject matter experts in the areas of large-‐scale organizational change, relationship management, quality management, and survey research. For more information about the Avoca Quality Consortium please contact [email protected] at (619) 994-‐8677, or visit the The Avoca Quality Consortium.